Anika Therapeutics, Inc.(ANIK)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,350 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in ANIK
Events flagged as statistical outliers against ANIK's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-07-31
ANIK quality score jumped 10 points (25→36) on a new filing
View source filing →
ANIK Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Anika Therapeutics, Inc. (ANIK), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ANIK at 34.4/100 on a 32-signal composite quality model, placing it at rank #2,350 of 2,961 stocks — the bottom half of the AI-ranked universe. ANIK scores in the top quartile across earnings quality (76.3). Areas of concern include institutional flow (15.9) and revenue scale (18.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 17.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Anika Therapeutics, Inc. reports quarterly revenue of $32.6M, net income of $3.3M, free cash flow of $-2.1M. Top institutional holders of ANIK by reported 13-F value include BlackRock, Caligan Partners, MORGAN STANLEY, based on the most recent SEC filings. ANIK trades on the Nasdaq exchange and files with the SEC under CIK 898437. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ANIK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Anika Therapeutics, Inc. directly from SEC EDGAR. Anika Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 19 and 41 since 2021, currently 34.4 — a stable long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$32.6M
Net Income
Q2 2026
$3.3M
Free Cash Flow
Q2 2026
$-2.1M
ROIC
Q2 2026
8.6%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-5.9% YoYNet Income
+80.7% YoYOperating Income
-116.6% YoYEPS (Diluted)
+80.2% YoYTotal Assets
-6.2% YoYOp. Cash Flow
+107.1% YoYFree Cash Flow
+287.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $112.8M -5.9% | $119.9M -0.7% | $120.8M +6.1% | $113.8M -23.0% | $147.8M +13.3% | $130.5M |
| Net Income | $-10.9M +80.7% | $-56.4M +31.8% | $-82.7M -456.3% | $-14.9M -459.4% | $4.1M +117.2% | $-24.0M |
| Operating Income | $-11.1M -116.6% | $-5.1M -704.4% | $844.0K -77.0% | $3.7M +40.3% | $2.6M +109.2% | $-28.3M |
| EPS (Diluted) | $-0.76 +80.2% | $-3.83 +32.1% | $-5.64 -452.9% | $-1.02 -464.3% | $0.28 +116.6% | $-1.69 |
| Total Assets | $190.3M -6.2% | $202.7M -25.1% | $270.6M -22.5% | $349.1M +0.5% | $347.5M -4.9% | $365.6M |
| Operating Cash Flow | $11.2M +107.1% | $5.4M +402.2% | $-1.8M -140.6% | $4.4M -47.5% | $8.4M -35.7% | $13.1M |
| Free Cash Flow | $4.4M +287.1% | $-2.3M +67.7% | $-7.2M -134.5% | $-3.1M -194.6% | $3.3M -71.5% | $11.4M |
Get alerted when ANIK's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Anika Therapeutics, Inc. including:
Top Institutional Holders of ANIK
BlackRock, Inc.
$21.2M1,449,671 shCaligan Partners LP
$21.0M1,435,130 shMORGAN STANLEY
$9.0M614,320 shACADIAN ASSET MANAGEMENT LLC
$8.9M606,544 shVANGUARD CAPITAL MANAGEMENT LLC
$8.4M572,113 shAQR CAPITAL MANAGEMENT LLC
$8.2M559,846 shBOOTHBAY FUND MANAGEMENT, LLC
$7.7M529,640 shRENAISSANCE TECHNOLOGIES LLC
$7.0M481,417 shDIMENSIONAL FUND ADVISORS LP
$6.6M451,095 shCAPITAL MANAGEMENT CORP /VA
$6.6M448,474 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $21.2M | 1,449,671 |
| Caligan Partners LP | $21.0M | 1,435,130 |
| MORGAN STANLEY | $9.0M | 614,320 |
| ACADIAN ASSET MANAGEMENT LLC | $8.9M | 606,544 |
| VANGUARD CAPITAL MANAGEMENT LLC | $8.4M | 572,113 |
| AQR CAPITAL MANAGEMENT LLC | $8.2M | 559,846 |
| BOOTHBAY FUND MANAGEMENT, LLC | $7.7M | 529,640 |
| RENAISSANCE TECHNOLOGIES LLC | $7.0M | 481,417 |
| DIMENSIONAL FUND ADVISORS LP | $6.6M | 451,095 |
| CAPITAL MANAGEMENT CORP /VA | $6.6M | 448,474 |
Companies Similar to ANIK
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Sight Sciences, Inc.
Verrica Pharmaceuticals Inc.
Centessa Pharmaceuticals plc
ANGIODYNAMICS INC
CASTLE BIOSCIENCES INC
Vanda Pharmaceuticals Inc.
STAAR SURGICAL CO
ASCENT INDUSTRIES CO.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put ANIK on your watchlist
Track score changes the day Anika Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ANIK a good stock to buy?
13F Pro's AI-powered analysis of Anika Therapeutics, Inc. (ANIK) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ANIK are available on the ANIK stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ANIK is classified as a small company.
Which hedge funds own ANIK?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ANIK. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Anika Therapeutics, Inc.'s investment landscape.